GlassScriptPhysician profile
Ryan P Wencl
NPI 1740936046
$3,191.48
in general payments reported to CMS, 2019-2025
16 companies · $513 in 2025
The $513 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $748 · 2023: $945 · 2024: $985 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.34 | 2022-2025 | |
| Lilly USA, LLC | $707.23 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $449.41 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $277.69 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $262.78 | 2023-2024 | Farxiga, Airsupra |
| Amgen INC. | $181.75 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.06 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.66 | 2024-2025 | Caplyta |
| Alk-Abello, INC | $62.65 | 2024 | Grastek, Odactra, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $51.96 | 2022-2023 | Trintellix |
| Lundbeck LLC | $50.32 | 2022-2024 | Brintellix, Rexulti |
| Pfizer INC. | $24.13 | 2024 | |
| Axsome Therapeutics, INC. | $20.69 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.82 | 2022 | |
| Novo Nordisk INC | $17.90 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $15.09 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wencl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.